טרג'נטה דואו 2.5 מג1000 מג
boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - טבליות מצופות פילם - linagliptin 2.5 mg; metformin hydrochloride 1000 mg - metformin
אבנדמט 4 מ"ג/1000 מ"ג
glaxo smith kline (israel) ltd - metformin hydrochloride 1000 mg; rosiglitazone as maleate 4 mg - tablets - metformin and rosiglitazone - avandamet is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus : as dual combination therapy in patients who are already treated with combination rosiglitazone and metformin or who are not adequately controlled on metformin alone or in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea.
נובוגרד 1 מ"ג/500 מ"ג
novo nordisk ltd - metformin hydrochloride 500 mg; repaglinide 1 mg - tablets - metformin - novogard is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 mellitus who are already treated with a meglitinide and metformin hcl or who have inadequate glycemic control on a meglitinide alone or metformin hcl alone.
נובוגרד 2 מ"ג/500 מ"ג
novo nordisk ltd - metformin hydrochloride 500 mg; repaglinide 2 mg - tablets - metformin - novogard is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 mellitus who are already treated with a meglitinide and metformin hcl or who have inadequate glycemic control on a meglitinide alone or metformin hcl alone.
יוקריאס 50/500 מ"ג
novartis pharma services ag - metformin hydrochloride 500 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
סיטאמין טבע 50 מג 1000 מג
teva israel ltd - metformin hydrochloride; sitagliptin as phosphate - טבליות מצופות פילם - sitagliptin as phosphate 50 mg; metformin hydrochloride 1000 mg - metformin
סיטאמין טבע 50 מג 500 מג
teva israel ltd - metformin hydrochloride; sitagliptin as phosphate - טבליות מצופות פילם - sitagliptin as phosphate 50 mg; metformin hydrochloride 500 mg - metformin
ג'נואט 50/1000 מ"ג טבליות
merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.
ג'נואט 50/1000 מ"ג טבליות
merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.
ג'נואט 50/1000 מ"ג טבליות
merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.